Secukinumab
CAIN457F2306E1
Phase 3 small_molecule completed
Quick answer
Secukinumab for Psoriatic Arthritis is a Phase 3 program (small_molecule) at Novartis Pharmaceuticals with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Pharmaceuticals
- Indication
- Psoriatic Arthritis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed